Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Blogs about Biotechnology, Pharmaceutical and Healthcare

17:41 EDT 24th July 2014 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 52,000+

Thursday 24th July 2014

Genomics startup allies with Illumina

San Diego's Cipher Genomics also brings top biotech executives on board.

Health Net, Inc. (HNT): Potential to Be Huge Winners Says Bank of America

As of this keystroke, Health Net, Inc. (NYSE: HNT) shares are up around 4% on the day. The managed health care services provider is the beneficiary, at least in part, from an upgrade form Bank of America.[More...]

World’s first Malaria Vaccine Submitted for Approval to EMA

GlaxoSmithKline submits the first malaria vaccine for approval by the European Medicines Agency and the World Health Organization The vaccine, named RTS,S, targets Plasmodium falciparum parasite. This parasite is most commonly found in sub-Saharan, where 90% of malaria related deaths occur. Children under 5 account for 77% of the deaths. The vaccine uses the AS01 adjuvant […]

Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript

Alexion Pharmaceuticals (NASDAQ:ALXN) Q2 2014 Earnings Call July 24, 2014 10:00 am ET Executives Irving Adler - Executive Director of Corporate Communications Leonard Bell - Co-Founder, Chief Executive Officer, Treasurer and Director Vikas Sinha - Chief Financial Officer and Executive Vice President David L. Hallal - Chief Commercial Officer and Executive Vice President Martin MacKay - Global...

Boston Scientific's (BSX) CEO Michael Mahoney on Q2 2014 Results - Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q2 2014 Results Earnings Conference Call July 24, 2014 8:00 a.m. ET Executives Susan Lisa - Investor Relations Michael Mahoney - President and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Keith Dawkins - Global Chief Medical Officer and Executive Vice President Ken Stein - Senior Vice President and Associ...

Top 3 Sparks of Interest for Leading Vaccine Academics

Recently we undertook the research for the 15th annual World Vaccine Congress. As part of that research, we spoke to leading vaccine academics from the likes of University of Oxford and Erasmus MC to find out what they thought were the most interesting trends in industry at the moment. These were the top 3: 1. […]

The Fed Calls Out Biotech... Is It Time To Sell?

When the world’s top central banker speaks, markets pay very close attention.Last week, Federal Reserve Chair Janet Yellen was on Capitol Hill delivering her semi-annual testimony on monetary policy.And in her remarks she stuck mostly to the script signaling that a high degree of monetary policy accommodation remains appropriate for a "considerable time."Too much slack in the labor market, low w...

Cypher Genomics’ Analytics Tech Gains Some Cred in Illumina Deal

Chemed's (CHE) CEO Kevin McNamara on Q2 2014 Results - Earnings Call Transcript

Chemed Corporation (NYSE:CHE) Q2 2014 Earnings Conference Call July 24, 2014 10:00 AM ET Executives Sherri Warner – IR Kevin McNamara – President and CEO Dave Williams – EVP and CFO Tim O’Toole – CEO, VITAS Healthcare Corporation Analysts Darren Lehrich – Deutsche Bank Frank Morgan – RBC Capital Markets Jim Barrett – C.L. King & Associates Presentation Operato...

Why Owners Of Cigna Should Take Profits

By Clifton Bruce:Cigna Corp. (NYSE:CI) has been on a tear in the last three months. Current stock owners love this uptrend and hope to keep riding this wave, but at one point the wave will die out -- and I believe it's in a matter of weeks. The stock price is up 31.74% in just over three months and 11.82% YTD. Cigna keeps on rising, closing at an all-time high four out of the past five trading day...

Celgene's (CELG) CEO, Robert Hugin on Q2 2014 Results - Earnings Call Transcript

Celgene Corporation (NASDAQ:CELG) Q2 2014 Earnings Conference Call July 24, 2014 9:00 am ET Executives Robert Hugin – Chairman, Chief Executive Officer Jacqualyn Fouse – Executive Vice President, Chief Financial Officer Mark Alles – Global Head, Hematology and Oncology Scott Smith – Global Head, Inflammation and Immunology Patrick Flanigan – Vice President, Investor Relations Anal...

Personalized Medicine Challenges: Lagging Science Or Uninformed Physicians?

Congress hears mixed views on ways to advance the field as regulators, industry and academics offer differing opinions on obstacles.

Quest Diagnostics' (DGX) CEO Stephen Rusckowski on Q2 2014 Results - Earnings Call Transcript

Quest Diagnostics Inc (NYSE:DGX) Q2 2014 Earnings Conference Call July 24, 2014 8:30 AM ET Executives Dan Haemmerle - Executive Director Investor Relations Stephen H. Rusckowski - President and Chief Executive Officer Mark J. Guinan - Senior Vice President and Chief Financial Officer Analysts Gavin S. Weiss – JP Morgan Securities LLC Bret Jones – Oppenheimer & Co Robert M. Will...

With Great Opportunity Comes Great Challenges in the 3-D Printing Space

Spider-Man fans know that with great power comes great responsibility. The same could be said of using 3-D printing, also known as additive manufacturing, in the medical field. For as many opportunities as 3-D printing offers, the industry has to tackle a host of regulatory, financial, and legal challenges before the technology can be fully […] The post With Great Opportunity Comes Great Cha...

Content is for Your Customers

One of the biggest pitfalls of content creation – and by far the biggest content mistake by amateur life science marketers – is forgetting that your content isn’t just directed AT your target audience, but is FOR your target audience. Many content creators focus too heavily on what they want their customers to hear rather […]

Sarepta Abruptly Fires CSO and RNA Vet Krieg

Sarepta Therapeutics is already one of the most controversial, volatile stocks in the biotech sector. And the Cambridge, MA-based company is in for another rocky day today, as a regulatory filing revealed that the company has axed chief scientific of...

RTI Surgical's (RTIX) CEO Brian Hutchison on Q2 2014 Results - Earnings Call Transcript

RTI Surgical Inc. (NASDAQ:RTIX) Q2 2014 Earnings Conference Call July 24, 2014 8:30 AM ET Executives Wendy Crites Wacker – IR Brian Hutchison – President and CEO Rob Jordheim – EVP and CFO Carrie Hartill – EVP and CSO Analysts Chris Cooley – Stephens Dillon Hoover – Craig-Hallum Kyle Rose – Canaccord Jayson Bedford – Raymond James Presentation Operator Good day l...

A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval

ByDoctoRx:Gilead Sciences (NASDAQ:GILD) reported yet another record quarter Wednesday after the bell, of $2.36 per share, which compares with $1.48 in Q1 and much lower in Q2 2013 (all data non-GAAP). Sales of Sovaldi for hepatitis C reached $3.5 B, up by about half from Q1, and is already, in half a year, one of the most successful drug products in history. All records for a first-year launch hav...

3 Convincing Reasons To Buy Dendreon

By Renu Singh:Biotechnology company Dendreon (NASDAQ:DNDN) is not in good health in 2014. The company has lost around 30% of its market capitalization so far this year and its first-quarter results didn't inspire any confidence either, although they were marginally better as compared to last year. Dendreon's cancer drug, Provenge, turned in weak sales. As a result, despite cutting its losses in ha...

PharmAthene Vs. SIGA: Rebutting G. Hudson's 'Potential Award' Article

By Jeff Eiseman:G. Hudson just published an article about the outcome of the suit between PharmAthene (NYSEMKT:PIP) and SIGA Technologies (NASDAQ:SIGA). The context is that in 2011, Vice Chancellor Parsons ruled that SIGA had both violated the doctrine of promissory estoppel and breached its contractual obligation to negotiate in good faith. He imposed a remedy consisting of an income stream that...

Sanford-Burnham commends summer 2014 high-school researchers

On July 18, eleven students from The Preuss School UCSD celebrated the completion of an intensive two-week summer research program with a poster symposium and luncheon at our La Jolla, Calif., campus.

Invacare's (IVC) CEO Gerry Blouch on Q2 2014 Results - Earnings Call Transcript

Invacare Corporation (NYSE:IVC) Q2 2014 Earnings Conference Call July 24, 2014 08:30 am ET Executives Gerry Blouch - President, Chief Executive Officer, Director Rob Gudbranson - Chief Financial Officer, Senior Vice President, Treasurer Lara Mahoney - Director of Investor Relations and Corporate Communications Analysts Bob Labick - CJS Securities Matthew Mishan - KeyBanc Jim Sidoti - Sido...

BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats

The unfortunate few infected by Ebola learn quickly that the rare disease is a near-certain death sentence. Outbreaks have led to fatality rates up to 90 percent, according to the World Health Organization. Treatment options are limited: no approved...

Zacks' Bull Of The Day: Acadia Healthcare

By Zacks Investment Research: Acadia Healthcare (NASDAQ:ACHC) provides inpatient behavioral health care services, including psychiatric and chemical dependency services. The stock became a Zacks #1 Rank this month after significant bumps in analyst earnings estimates for this year and next, with 2014 EPS projections moving up to $1.44 from $1.30, representing 34% annual growth. And 2015 estimates...

Reflections on RTP

Having moved to the Research Triangle Park region in 1987 when my husband was recruited to Glaxo, I now realize that we chose “the right place at the right time.” I started a post-doctorial fellowship at UNC-Chapel Hill and eventually became a cl...

Search BioPortfolio: